Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605397 · ClinicalTrials.gov registry record · Phase 1
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00605397: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00605397 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00605397, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab. This is a radioactive tracer that was developed at MSKCC to target HER2 protein on cancer cells. A radioactive tracer is a small amount of radioactive dye that follows something else that is not radioactive In this study the study agent, 64Cu-trastuzumab, is the tracer and what's being followed is trastuzumab (Herceptin™). By giving you this tracer after you have treatment with trastuzumab (Herceptin™), we will be able to use PET scans to show us which parts of your body and tumor sites the Herceptin goes to. This will help us to understand better how Herceptin works in the body to fight cancer.
Interventions
- RADIATION PET Imaging With Cu-64 Labeled Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605397
The ClinicalTrials.gov registry entry for NCT00605397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET Imaging With Cu-64 Labeled Trastuzumab is the first listed.
NCT00605397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605397 about?
NCT00605397 is a clinical study titled "PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer". The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab. This is a radioactive tracer that was developed at MSKCC to target HER2 protein on cancer cells. A radioactive tracer is a small amount of radioactive d...
What is the current status of trial NCT00605397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00605397?
The interventions under investigation include: PET Imaging With Cu-64 Labeled Trastuzumab (RADIATION).
Who is sponsoring clinical trial NCT00605397?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.